Despite opposition from many stakeholders, a bipartisan contingent of Congress, and CMS’ own advisory panel,the agency is moving forward with its plan to drastically cut payments for drugs acquired through the 340B drug discount program, according to the 2018 OPPS final rule, released November 1.
The Food and Drug Administration (FDA) approved the first gene therapy released in the U.S., Kymriah, also known as chimeric antigen receptor T-cell (CAR-T) therapy.
This document provides guidance on key performance indicators for denials management and revenue integrity, including calculations for denials rates and denials overturn ratios.
